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The inheritance of a G allele in position 61 in the 50UTR of the epidermal growth factor (EGF) gene has been reported
to increase melanoma susceptibility, a ﬁnding we have investigated in this study. The most potent phenotypic risk
factor for melanoma is the atypical mole syndrome (AMS) phenotype. Our hypothesis is that the AMS is genetically
determined and that nevus genes are also low penetrance melanoma susceptibility genes. We report that the G
allele frequencies were the same in 697 healthy women and 380 melanoma cases (OR 0.97, 95% CI 0.8–1.2 p¼ 0.76).
We therefore found no evidence that this polymorphism is a melanoma susceptibility gene. Furthermore, we found
no evidence that the polymorphism controls the nevus phenotype (nevus number, number atypical nevi or AMS
phenotype). We did ﬁnd some evidence that the G allele may be associated with decreased tumor Breslow thick-
ness (OR 0.5, 95% CI 0.3–0.9) for the A/A genotype versus A/G and G/G combined in tumors of thickness 43.5 vs
p3.5 mm and may therefore act as a predictor of survival, although this ﬁnding is not in accord with the original
report. This is the second study to ﬁnd no association between EGF þ 61 and melanoma susceptibility.
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Although the identification of high penetrance melanoma
susceptibility genes, such as CDKN2A (Goldstein and Tuck-
er, 1997) CDK4 (Zuo et al, 1996), and p14ARF (Randerson-
Moor et al, 2001) has been fruitful in recent years, the iden-
tification of low penetrance melanoma susceptibility genes
has to date proved challenging. MC1R variants have
certainly been established as susceptibility genes for
melanoma (Valverde et al, 1996) and these variants have
furthermore been shown to modify the penetrance of the
high penetrance gene CDKN2A (Box et al, 2001; van der
Velden et al, 2001). Candidate gene approaches to identi-
fying others have so far been less persuasive. There is ev-
idence for (Aitken et al, 1999; Kumar et al, 2001) and against
(Bertram et al, 2002) different polymorphisms in CDKN2A as
a melanoma or nevus susceptibility gene. There are con-
flicting data on the role of genes coding for detoxifying en-
zymes GSTM1 and CYP2D6 (Wolf et al, 1992; Dolzan et al,
1995; Lafuente et al, 1995; Strange et al, 1999; Kanetsky
et al, 2001), and an unconfirmed small effect of the vitamin
D receptor gene (Hutchinson et al, 2000). Suggestions that a
polymorphism in the DNA repair gene XRCC3 predisposed
to melanoma (Winsey et al, 2000) were not confirmed (Duan
et al, 2002; Bertram et al, 2004) and there is a single report
of the nucleotide excision repair gene XPD in association
with melanoma (Tomescu et al, 2001). A report of a p53
polymorphism in association with melanoma remains to be
repeated (Shen et al, 2003). Most recently a study was
published which suggested that polymorphisms in the
BRAF gene might predispose to melanoma (Meyer et al,
2003). The observation, however, was made for males but
was not present for females and therefore clearly needs to
be assessed in another population.
The epidermal growth factor (EGF) gene, located at
4q25–27, has recently been proposed to be a melanoma
susceptibility gene (Shahbazi et al, 2002) although the find-
ings reported were not confirmed recently by another UK
group (McCarron et al, 2003). The original study identified
an A to G polymorphism in the 50UTR (position 61) of the
EGF gene, which appeared to be associated with an in-
crease in EGF production in vitro, an increased risk of
melanoma, and an increase in tumor Breslow thickness
(Shahbazi et al, 2002). Consequently, the authors suggested
that the EGF 50UTR A61G polymorphism might act as a
marker for both melanoma risk and outcome. We conduct-
ed a similar case–control study, using a substantially larger
series of incident melanoma cases, in order to investigate
the findings of Shahbazi et al.
The most potent phenotypic risk factor for melanoma is
the atypical nevus phenotype (Swerdlow et al, 1986; Bataille
et al, 1996). Twin studies have shown that nevi are primarily
genetically determined (Easton et al, 1991; Zhu et al, 1999;
Wachsmuth et al, 2001) and our hypothesis is therefore that
genes controlling nevus phenotype may act as melanoma
susceptibility genes. In addition, we also therefore assessed
the possible role for the EGF polymorphism as a nevus
susceptibility gene.
Abbreviations: AMS, atypical mole syndrome; EGF, epidermal
growth factor
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Results
Genotyping was successful in 669 (96%) controls and 380
(100%) cases (summarized in Table I). The genotypes ob-
served in the Yorkshire, St Albans and the total control
groups were all found to be in Hardy–Weinberg equilibrium
(p¼ 0.62, 0.37, and 0.34, respectively). The EGF genotype
and allele frequencies of the incident melanoma cases
(n¼ 380) were not significantly different from the controls
(n¼ 669, p¼0.80 and 0.76 respectively). Furthermore, the
genotype and allele frequencies of the female incident me-
lanoma cases did not significantly differ from the controls
(p¼ 0.94, 0.94). Genotype analysis carried out only on con-
trols recruited from the Yorkshire region (n¼389) showed
no significant difference from that observed in the incident
melanoma cases (p¼0.79). The frequency of the G allele
(0.42) was comparable to that reported by Shahbazi et al for
their 99 controls (0.44). There was no evidence of an as-
sociation between heterozygous (AG) or homozygous (GG)
genotype and melanoma status when comparing the inci-
dent melanoma cases with the controls (OR¼1.03, [95% CI
0.77–1.39]; OR¼0.91, [95% CI 0.61–1.37], respectively) or
with just the Yorkshire controls (OR¼1.10, 95% CI (0.79–
1.53); OR¼ 0.99, 95% CI (0.63–1.56), respectively, Table I).
An overall test of association between genotype and
Breslow thickness gave non-significant evidence of asso-
ciation (Fisher’s exact test, p¼0.08). In contrast to Shah-
bazi et al, however, we observed that the A/A genotype
appeared more frequently and the G/G genotype less fre-
quently in patients with thick tumors (43.5 mm) at pre-
sentation (Table II). Shahbazi et al reported a positive
association between the G/G genotype and thick tumors
(OR 3.7 (95% CI 1.0–13.2), p¼ 0.045), whereas the corre-
sponding estimated OR from our data is 0.58 (95% CI
0.17–1.57). Performing a post hoc contrast between the A/G
and G/G genotypes combined and the A/A genotype we
find an OR of 0.47 (95% CI 0.25–0.91, p¼0.014, Table II)
for thicker tumors and a negative association between
the presence of the G allele and a Breslow thickness of
43.5 mm (OR 0.60 (95% CI 0.37–0.96), p¼ 0.026).
There was no association between genotype and the
mean total number of banal or atypical nevi in either the
healthy women (p¼0.90 and 0.65, respectively) or in cases
(p¼ 0.43 and p¼ 0.79, Table III). There was no association
between the polymorphism and AMS score in either the
cases or healthy women (p¼0.66 and 0.83, respectively).
Discussion
We have found no evidence to support the findings of
Shahbazi et al (2002), that the 50UTR A61G polymorphism of
the EGF is associated with melanoma risk. Indeed, the CI
for the GG genotype (which was the only group in which the
previous study found an association with melanoma) in our
study did not overlap with that of Shahbazi et al, showing
that the two studies are formally inconsistent. This discrep-
ancy is not easily explainable. The cases for both studies
were recruited from similar Caucasian UK populations, al-
though 43% of those recruited by Shahbazi et al were not
incident cases. The genotype frequencies in the controls in
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this study were not significantly different from those seen in
controls in Shahbazi et al (p¼ 0.68). Our study had over
99% power to detect an association of the size reported by
Shahbazi et al and a power of 89% to detect a more modest
OR of melanoma of 1.6 to carriers of a G allele compared
with non-carriers.
A possible explanation for this discrepancy is the com-
position of the Shahbazi et al case set (77 new cases and 58
undergoing follow-up) leading to an underrepresentation of
tumors with a Breslow thickness43.5 mm (n¼ 12/135; 9.4%
vs an expected 17.1%). (Patients with tumors 43.5 mm
have a poorer prognosis and are therefore less likely to
be seen in follow-up clinics). An under-representation of
thicker tumors could bias the results if the G allele was
correlated with Breslow thickness as was suggested by
Shabhazi et al. These authors were aware of the possible
bias by Breslow thickness but were reassured that the bias
was unlikely to be problematic as their results suggested
that the G allele was associated with greater Breslow thick-
ness, which would have reduced the relative risk for me-
lanoma rather than increasing it. In our study this relation-
ship with Breslow thickness, however, was not confirmed.
This under representation of thick tumors was not observed
in our sample set of cases recruited at first presentation
(n¼ 50/363; 13.8%).
Shahbazi et al also reported that the 61G allele is as-
sociated with increased EGF production. Whilst the issue of
EGF production has not been addressed in our study, our
findings with regard to Breslow thickness are discrepant to
those reported by Shahbazi et al and by McCarron et al,
although the correlation in the latter study was more modest
than in the original report. Our study would suggest if any-
thing, that the relationship between the G allele and Bres-
low thickness was the reverse of that suggested by the
previous study. Overall then, the evidence that this EGF
polymorphism may have an effect on tumor thickness is
weak and much larger studies will be necessary to resolve
this question.
We and another UK group (McCarron et al, 2003) have
found no evidence to confirm a polymorphic form of the
EGF gene as a low penetrance melanoma susceptibility or a
nevus gene in a similar population.
Materials and Methods
Study population Three hundred and eighty population-based
incident melanoma cases were recruited in Yorkshire, UK in the
period since September 2001 till December 2002. Six hundred and
ninety-seven female healthy controls aged 19–46 years were re-
cruited via GPs from Yorkshire (n¼ 396) and an area of the UK
approximately 200 miles south of Yorkshire (around St Albans,
Hertfordshire) (n¼ 301), in a study to identify nevus genes (Bertram
et al, 2004). These women formed the comparison group. As cases
were both male and female but controls were female, case–control
comparisons were carried out additionally in females alone, al-
though there was no a priori reason to suppose that sex would
have an effect. Written informed consent was obtained from all
participating individuals and institutional and regional ethical com-
mittee approval was obtained.
All subjects were examined by nurse examiners, and their ne-
vus phenotype was determined as described in previous studies
(Bertram et al, 2002). Nevi 2mm or greater in number were counted
and the number of atypical nevi recorded. The AMS score, as a
measure of the overall phenotype, was calculated as reported
previously (Newton Bishop et al, 1994). Hair and eye color were
recorded. A blood or buccal cell sample was taken for the isolation
of DNA.
Genotyping We designed an ARMS test for the allele-specific
amplification of the EGF A61G variant. A common forward primer
50-CAT TTG CAA ACA GAG GCT CA-30 and an allele specific re-
verse primer, 50-GAA CTG ATG GAA AGT TCC ACC C-30 (G allele)
or 50-GAA CTG ATG GAA AGT TCC ACC T-30 (A allele) were used to
amplify a 186 bp band. A second internal mismatch (wobble base)
was included in the reverse primers (third base from 30 end) to
minimize non-specific binding of the primers. A second product of
236 bp (human growth hormone gene, hGH) was co-amplified with
the test product to provide an internal amplification control (for-
ward, 50-GAG TTT GTA AGC TCT TGG GGA AT-30; reverse, 50-TCC
TTT GGG ATA TAG GCT TCT TC-30). All gels were scored blind
independently by two individuals. Over 15% of samples were am-
plified in duplicate and the results were 499% concordant.
Statistical analyses Hardy–Weinberg equilibrium was tested for
in the control samples using a w2 goodness-of-fit test. Genotype
and allele frequencies were compared using w2 tests. ORs and
exact 95% CI were calculated to estimate the association between
genotype and melanoma status. The association between geno-
type and Breslow thickness was analyzed using w2 tests using the
same categories of tumor thickness as Shahbazi et al (Shahbazi et
al, 2002) (o1.5 mm, 1.5–3.5 mm, and 43.5 mm), except that we
did not include patients with in situ tumors in our study. Differences
in numbers of benign and atypical nevi between groups were in-
vestigated using t-tests or analysis of variance on log-transformed
values. Dependence of the AMS score on genotype was analyzed
using ordinal logistic regression. Analyses were carried out in
STATA (StataCorp, 2001).
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